Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. (Nasdaq: PWUP) is a blank-check company focused on the biopharmaceutical sector. The company filed a definitive proxy statement (DEF 14A) with the SEC on May 8, 2026, a filing type typically associated with seeking shareholder approval for a proposed business combination or related corporate actions. PWUP targets opportunities in biopharma and life sciences, a sector that has drawn sustained SPAC activity in recent years. The company's current status reflects an active deal process as disclosed through its most recent SEC filings. Investors and analysts tracking the SPAC market can sign up at SpacDesk for full data, filings history, and real-time deal status on PWUP and hundreds of other active blank-check companies.